Inmune Bio, Inc.

Public companies file this within four business days when something important happens that investors should know about before the next quarterly report.

Inmune Bio, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. htm PRESS RELEASE DATED JUNE 2, 2026 Exhibit 99. 1 INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.